{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=cemiplimab%2Bfianlimab", "query": { "intervention": "cemiplimab+fianlimab" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 34, "total_pages": 4, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=cemiplimab%2Bfianlimab&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-01T16:08:41.029Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06190951", "title": "A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "cemiplimab", "type": "DRUG" }, { "name": "Fixed Dose Combination (FDC) cemiplimab+fianlimab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 151, "start_date": "2024-09-18", "completion_date": "2030-12-09", "has_results": false, "last_update_posted_date": "2026-02-10", "last_synced_at": "2026-09-01T16:08:41.029Z", "location_count": 28, "location_summary": "La Jolla, California • Los Angeles, California • Newport Beach, California + 22 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06190951" }, { "nct_id": "NCT05608291", "title": "A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "Fianlimab", "type": "DRUG" }, { "name": "Cemiplimab", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 1564, "start_date": "2023-01-16", "completion_date": "2030-04-03", "has_results": false, "last_update_posted_date": "2026-07-06", "last_synced_at": "2026-09-01T16:08:41.029Z", "location_count": 28, "location_summary": "La Jolla, California • San Francisco, California • Santa Monica, California + 21 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Englewood", "state": "Colorado" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05608291" }, { "nct_id": "NCT06918132", "title": "Cemiplimab and Fianlimab Before Surgery for the Treatment of Stage IB-IIIB Non-Small Cell Lung Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lung Non-Small Cell Carcinoma", "Stage IB Lung Cancer AJCC v8", "Stage II Lung Cancer AJCC v8", "Stage IIIA Lung Cancer AJCC v8", "Stage IIIB Lung Cancer AJCC v8" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Cemiplimab", "type": "BIOLOGICAL" }, { "name": "Fianlimab", "type": "BIOLOGICAL" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Surgical Procedure", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2025-04-29", "completion_date": "2027-04-29", "has_results": false, "last_update_posted_date": "2026-02-24", "last_synced_at": "2026-09-01T16:08:41.029Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT06918132" }, { "nct_id": "NCT07414992", "title": "A Study of Radiation Therapy and Cemiplimab With or Without Fianlimab In People With Bladder Cancer", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Bladder Urothelial Carcinoma" ], "interventions": [ { "name": "Stereotactic body radiotherapy", "type": "RADIATION" }, { "name": "Cemiplimab", "type": "DRUG" }, { "name": "Cemiplimab and Fianlimab", "type": "DRUG" }, { "name": "Radical cystectomy", "type": "PROCEDURE" } ], "intervention_types": [ "RADIATION", "DRUG", "PROCEDURE" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 44, "start_date": "2026-09", "completion_date": "2028-03", "has_results": false, "last_update_posted_date": "2026-08-18", "last_synced_at": "2026-09-01T16:08:41.029Z", "location_count": 7, "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "Harrison", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07414992" }, { "nct_id": "NCT07511036", "title": "PROSECCO: A Phase 2, Single Arm, Neoadjuvant Study Evaluating Combination Cemiplimab, Fianlimab, And Ipilimumab In Patients With Surgically Resectable Melanoma", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "Cemiplimab", "type": "DRUG" }, { "name": "Lpilimumab", "type": "DRUG" }, { "name": "Fianlimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2026-09-01", "completion_date": "2030-05-24", "has_results": false, "last_update_posted_date": "2026-04-06", "last_synced_at": "2026-09-01T16:08:41.029Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07511036" }, { "nct_id": "NCT07223411", "title": "Opdualag vs. Cemiplimab/Fianlimab in Relation to the Immunological Response in Tumor and Peripheral Blood in Unresectable or Metastatic Melanoma", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Locally Advanced Melanoma" ], "interventions": [ { "name": "Fianlimab + Cemiplimab", "type": "DRUG" }, { "name": "Relatlimab + Nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "John Kirkwood", "sponsor_class": "OTHER", "healthy_volunteers": null, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2025-11-19", "completion_date": "2031-11-01", "has_results": false, "last_update_posted_date": "2025-11-26", "last_synced_at": "2026-09-01T16:08:41.029Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT07223411" }, { "nct_id": "NCT05785767", "title": "A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Advanced Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "fianlimab", "type": "DRUG" }, { "name": "cemiplimab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 149, "start_date": "2023-06-30", "completion_date": "2027-09-28", "has_results": false, "last_update_posted_date": "2026-07-02", "last_synced_at": "2026-09-01T16:08:41.029Z", "location_count": 23, "location_summary": "Tucson, Arizona • Yuma, Arizona • Redlands, California + 20 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Yuma", "state": "Arizona" }, { "city": "Redlands", "state": "California" }, { "city": "Norwich", "state": "Connecticut" }, { "city": "Clermont", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05785767" }, { "nct_id": "NCT07281768", "title": "Capecitabine/Oxaliplatin Chemotherapy and Cemiplimab With or Without Fianlimab or REGN7075 in Locally Advanced Rectal Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colorectal Cancer" ], "interventions": [ { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Cemiplimab", "type": "DRUG" }, { "name": "Fianlimab", "type": "DRUG" }, { "name": "REGN7075", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 66, "start_date": "2026-07-14", "completion_date": "2030-07", "has_results": false, "last_update_posted_date": "2026-07-21", "last_synced_at": "2026-09-01T16:08:41.029Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT07281768" }, { "nct_id": "NCT06699602", "title": "A Study of Cemiplimab and Fianlimab in People With Clear Cell Renal Cell Carcinoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Renal Cell Carcinoma" ], "interventions": [ { "name": "Cemiplimab", "type": "DRUG" }, { "name": "Fianlimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2025-02-11", "completion_date": "2028-02", "has_results": false, "last_update_posted_date": "2026-03-04", "last_synced_at": "2026-09-01T16:08:41.029Z", "location_count": 7, "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "Harrison", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06699602" }, { "nct_id": "NCT06787612", "title": "Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ovarian Cancer", "Fallopian Tube Cancer", "Primary Peritoneal Cancer" ], "interventions": [ { "name": "Ubamatamab", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Cemiplimab", "type": "DRUG" }, { "name": "Fianlimab", "type": "DRUG" }, { "name": "PLD", "type": "DRUG" }, { "name": "Sarilumab", "type": "DRUG" }, { "name": "REGN10597", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 297, "start_date": "2025-05-28", "completion_date": "2028-06-30", "has_results": false, "last_update_posted_date": "2026-08-12", "last_synced_at": "2026-09-01T16:08:41.029Z", "location_count": 21, "location_summary": "Birmingham, Alabama • La Jolla, California • Los Angeles, California + 17 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06787612" } ] }